Top Vascular Closure Device Companies

Global Vascular Closure Device Market size was valued at USD 2.08 Billion in 2024 and is poised to grow from USD 2.27 Billion in 2025 to USD 4.67 Billion by 2033, growing at a CAGR of 9.4% during the forecast period (2026–2033).

The market exhibitions a moderate level of merging, with a handful of major players imposing a significant share of the revenue. These key industry participants are advantageously intent on the introduction of innovative products to support their market positioning. Additionally, their focus extends to performing strategic initiatives, including partnerships, product launches, and collaborations, enhancing their overall market presence. 'Terumo Corporation (Japan) ', 'Abbott (U.S.) ', 'Teleflex Incorporated (U.S.) ', 'Haemonetics Corporation (U.S.) ', 'Vasorum Ltd. (Ireland) ', 'INVAMED (U.S.) ', 'Vivasure Medical Ltd. (Ireland) ', 'Medtronic (Ireland) ', 'Boston Scientific (U.S.) ', 'Cardinal Health (U.S.) ', 'Becton Dickinson (U.S.) ', 'B. Braun Melsungen (Germany) ', 'Cook Medical (U.S.) ', 'Merit Medical Systems (U.S.) ', 'AngioDynamics (U.S.) ', 'Asahi Intecc (Japan) ', 'Biotronik (Germany) ', 'Endologix (U.S.)'

Cardiovascular diseases (CVDs) stand as a prominent global cause of mortality, contributing significantly to the overall death toll. According to data from the American Heart Association (AHA), CVDs accounted for 18.6 million deaths in 2019, with a notable concentration in Eastern Europe and Central Asia. The AHA further forecasts that by 2030, approximately 40.5% of the United States population is expected to experience some form of CVD. This escalating prevalence of cardiovascular diseases is poised to drive the demand for catheterization and interventional procedures aimed at diagnosing and treating CVDs. The growing popularity of these procedures is anticipated to be a key driver propelling the market for vascular closure devices in the forthcoming years.

Increasing Distinction of Biodegradable Closure Devices: A remarkable trend in the Vascular Closure Device market is the increasing importance of biodegradable closure devices. These innovative devices represent a significant leap in vascular interference technology by incorporating biodegradable materials that undergo progressive disintegration, promoting natural healing processes. Biodegradable closure devices offer distinct advantages, such as reducing the long-term presence of foreign materials within the body, mitigating potential complications associated with permanent implants. Their biocompatible nature aligns with the growing emphasis on patient safety and comfort. The demand for biodegradable closure devices is on the rise, driven by their ability to provide effective vascular closure while addressing concerns related to long-term implantation, making them a promising avenue for enhancing patient outcomes in minimally invasive vascular procedures.

In the year 2022, North America held a significant share in the vascular closure device market, recording revenues surpassing USD 689 million. The region is poised for sustained growth until 2032, primarily driven by the heightened prevalence of cardiovascular diseases. The expanding population of elderly individuals, who exhibit a greater susceptibility to cardiovascular ailments, has prompted the establishment of advanced healthcare infrastructure in the region. Furthermore, the presence of extensive reimbursement coverage for medical procedures acts as a compelling incentive for both healthcare professionals and patients. This, in turn, encourages the adoption of innovative treatment alternatives and contributes substantially to the overall progress and advancement of the market.